1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2011, Issue 1
  5. Article
Volume 2011, Issue 1
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

To analyze the short term visual acuity and anatomic response after a single dose of off-label intravitreal injection of bevacizumab in diffuse diabetic macular edema (DME) not responding to conventionallaser photocoagulation.

Patients arid Methods: Prospective analysis of consecutive case series of 45 eyes of 38 patients with refractory diffuse DME who had one intra-vitreal injection of 1.25 mg of bevacizumab (Avastin) and followed up for 3 months. All patients passed at least six months since their last laser treatment before inclusion in the study. Patients underwent best corrected visual acuity determination, intraocular pressure measurement, stereoscopic biomicroscopy of the macula and measurement of the retinal thickness by optical coherence tomography (OCT) at base line and follow up visits.

Results: At 1 month post-injection, visual acuity improved by 1 line in 7 eyes, unchanged from the preinjection levels in 24 eyes and deteriorated in 14 eyes. At 3 months post injection, visual acuity improved in 18 eyes, it remained unchanged in 13 eyes and deteriorated in 14 eyes. The mean logMAR visual acuities were 0.60 (SD ± 0.34), 0.64 (SD ± 0.31) and 0.61 (SD ± 0.32) at pre-injection, at 1 month post-injection and at 3 months post-injection respectively; but this mean decrease in vision was statistically not significant (P value = 0.099). The foveal thickness on optical coherence tomography had decreased in 27 eyes and it increased in 18 eyes at 1 month post-injection. At 3 months following injection, foveal thickness was reduced in 34 eyes, but was increased in 11 eyes. The mean foveal thicknesses were 444.95 u (SD ± 127.36), 394.95 u (SD ± 138.03) and 378.32 u (SD ± 11 2.01) at pre-injection, 1 month post-injection and 3 months post-injection respectively. This decrease in the foveal thickness was statistically significant (P value <  0.001).

Conclusions: Intravitreal bevacizumab is effective in patients with diffuse DME which is refractory to treatment with conventional macular laser photocoagulation. Key words: bevacizumab, intravitreal, diffuse diabetic macular edema

© 2011 El Shafei, Pai, Al Hashimi, Warid, Farouk, licensee Bloomsbury Qatar Foundation Journals.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2011.1.10
2011-06-01
2025-01-19
Loading full text...

Full text loading...

References

  1. Bresnick GH. Diabetic macular edema. A review. Oph thalmology. 1986; 93::989–997.
     [Google Scholar]
  2. Browning DJ, Altaweel MM, Bressler NM, et al., Diabetic macular edema: What is focal and what is diffuse? Am J Ophthalmol. 2008; 146::649–655.
     [Google Scholar]
  3. Kang SW, Park CY, Ham Dl. The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant macular edema. Am J Ophthalmol. 2004; 137::313–322.
     [Google Scholar]
  4.   Diabetic Control and Complications Trail Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes millitus. N Engl J Med. 1993; 329::977–986.
     [Google Scholar]
  5. UK Prospective Diabetes Study Group, Tight blood pressure control and risk ofmacrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317::703–713.
     [Google Scholar]
  6.   Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Traetment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985; 103::1796–1806.
     [Google Scholar]
  7. Ferris FL III, Patz A. Macular Edema: a complication of diabetic retinopathy. Surv Ophthalmol. 1984; 28:suppl:452–461.
     [Google Scholar]
  8. Bresnick GH. Diabetic maculopathy: A critical review highlighting diffuse macular edema. Ophthalmology. 1983; 90::1301–1317.
     [Google Scholar]
  9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. En doer Rev. 2004; 25::581–611.
     [Google Scholar]
  10. Cunningham ET Jr, Adamis AP, Altaweel M. Macugen Diabetic Retinopathy Study Group. A phase II randomised double masked trial of pegaptanib, an anti-vascualr endothelial growth growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005; 112::1747–1757.
     [Google Scholar]
  11. Chun DW, Heier JS. Topping TM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant macular edema. Ophthalmology. 2006; 113::1706–1712.
     [Google Scholar]
  12. Haritoglou C, Kook D, Neubauer A, et al., Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006; 26::999–1005.
     [Google Scholar]
  13. Starita C, Patel M, Katz B, Adamis AP. Vasccular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy. Dev Ophthalmol. 2007; 39::122–148.
     [Google Scholar]
  14. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. MARINA Study Group, Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med. 2006; 355:14:1419–1431, Oct 5.
     [Google Scholar]
  15. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355::1432–1444.
     [Google Scholar]
  16. Klein R, Klein BE, Moss SE, et al., The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995; 102::7–16.
     [Google Scholar]
  17. Sophie JB, Peter KK, Hilei L. Pars plana vitrectomy for diabetic macular edema associated with posterior hyaloid traction. In: Peyman GAMeffert SAConway MD, eds. Vitreoretinal surgical techniques. Oxon, UK: Informa Healthcare 2007;:266–273.
     [Google Scholar]
  18. Negi AK, Vernon SA, Lim CS. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular edema refractory to laser photocoagulation. Eye. 2005; 19::747–751.
     [Google Scholar]
  19. Jonas JB, Martus P, Degenring RF. Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol. 2005; 123::1338–1343.
     [Google Scholar]
  20. Kumar A, Sinha S. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol. 2007; 55:6:451–455.
     [Google Scholar]
  21. Antcliff RJ, Marshall J. The pathogenesis of in diabetic maculopathy. Semin Ophthalmology. 1999; 14::223–232.
     [Google Scholar]
  22. Ferrara N, Hillan KJ, Gerber HP. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3::391–400.
     [Google Scholar]
  23. Soheilian M, Ramezani A, Bizanzadeh B. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina. 2007; 27::1187–1195.
     [Google Scholar]
  24. Arevalo FJ, Fromo-Guerra J, Quiroz-Mercuado H. Primary Intravitreal bevacizumab (Avastin) for diabetic macular edema. Results from the pan-American collaborative retina study group at 6-month followup. Ophthalmology. 2007; 114::743–750.
     [Google Scholar]
  25.   Diabetic Retinopathy Clinical Research Network. A phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema. Ophthalmology. 2007; 114::1860–1867.
     [Google Scholar]
/content/journals/10.5339/qmj.2011.1.10
Loading
  • Article Type: Research Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error